Studies to determine predictive biomarkers of response in patients with inflammatory bowel disease (IBD) and rheumatoid arthritis (RA) treated with TNF-α inhibitors are still developing; however, recent work has revealed potential biomarkers of response such as oncostatin M and increased switched memory B cells, respectively (38–40). The gene discussed is OSM; the disease is inflammatory bowel disease.